Last reviewed · How we verify
LVRNA009
LVRNA009 is an mRNA vaccine designed to stimulate immune responses against specific disease targets through encoded antigen expression.
At a glance
| Generic name | LVRNA009 |
|---|---|
| Sponsor | AIM Vaccine Co., Ltd. |
| Drug class | mRNA vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology/Oncology |
| Phase | Phase 3 |
Mechanism of action
As an mRNA vaccine candidate, LVRNA009 delivers messenger RNA encoding target antigens that are translated by host cells to trigger both CD8+ T-cell and antibody-mediated immune responses. The vaccine approach leverages lipid nanoparticle formulation technology to facilitate cellular uptake and promote innate immune activation alongside adaptive immunity.
Approved indications
Common side effects
Key clinical trials
- Clinical Trial of SARS-CoV-2 mRNA Vaccine in Chinese People (PHASE2)
- A Global Multi-center Clinical Study of SARS-CoV-2 mRNA Vaccine for the Prevention of COVID-19 (PHASE3)
- Clinical Trial of SARS-CoV-2 mRNA Vaccine(LVRNA009) as Heterologous Booster in Islamabad (PHASE3)
- Clinical Trial of SARS-CoV-2 mRNA Vaccine in China (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LVRNA009 CI brief — competitive landscape report
- LVRNA009 updates RSS · CI watch RSS
- AIM Vaccine Co., Ltd. portfolio CI